Therapeutics
Therapeutics testing overview
We have access to hundreds of assays to identify and monitor both prescribed and illicit drug use. Our cutting-edge evaluations use advanced and emerging technologies, including liquid chromatography tandem mass spectrometry (LC/MS/MS) and gas chromatography mass spectrometry (GS/MS), to deliver accurate, actionable results that clarify substance use for improved outcomes.
When you partner with Mayo Clinic Laboratories, you extend your network to include some of the world’s leading experts. Mayo Clinic clinicians, laboratorians, and genetic counselors are available to discuss testing options, interpret results, or help with case review and coordination.
Comprehensive disease testing
A collaboration with BioPharma Diagnostics includes access to the therapeutics testing capabilities of Mayo Clinic Laboratories, including:
- Addiction rehabilitation
- Alcohol biomarker testing
- Clinical and forensic technology
- Confirmatory testing
- Controlled substance monitoring
- Drug class testing
- Precision therapeutics
- Result interpretation
News and updates
The latest
Reviewing the challenges healthcare providers face in distinguishing between new and residual marijuana use in patients.
Register now: Aug. 13, 2025 - PACE/State of FL - The critical role of pharmacogenomics and therapeutic drug monitoring (TDM) in managing immunosuppressive therapy for solid organ transplant recipients.
Jessica Wright, Pharm.D., BCACP, explains how Mayo Clinic Laboratories' 3A5Q test helps determine initial tacrolimus doses for individuals after non-liver organ transplants. Optimal tacrolimus levels are one of the important factors in survival of the transplanted organ.
Kelly DuBois recently joined “Symptomatic: A Medical Mystery Podcast” to explain her health journey with Mayo Clinic. In the episode, Kelly, who faced a series of unexplained health issues over two decades, highlighted the help that Mayo Clinic was able to offer her after being misdiagnosed with acromegaly.
John Logan Black, M.D., explains how Mayo Clinic Laboratories' UGT1A1 tests (Mayo IDs: U1A1Q and UGTFZ) identify genetic variants that increase the risk of potentially life-threatening reactions to irinotecan, a chemotherapy agent.
PACE/State of FL - Substance use disorders and the common laboratory tests and matrices used for controlled substance monitoring.
Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' unique genetic tests identify patients at high risk of severe reactions to fluoropyrimidines — a type of chemotherapy drug. Test results can guide clinical decision-making for safer cancer treatment.
In a landmark discovery published in Clinical Chemistry, authenticated locks of hair from the composer Ludwig van Beethoven have revealed high lead concentrations after being analyzed at Mayo Clinic. Paul Jannetto, Ph.D., director of the Metals Laboratory at Mayo Clinic, along with his laboratory staff, completed testing on two independent and authenticated locks of Beethoven’s hair which confirmed the presence of high lead concentrations and could explain the cause for many of Beethoven’s ailments.
Paul Jannetto, Ph.D., explains the advantages that Mayo Clinic Laboratories' oral fluid drug screening offers over typical urine tests. Oral samples are easier to collect and harder to adulterate.
Tobacco use is the leading cause of preventable death in the United States. In this test-specific episode of the "Answers From the Lab" podcast, Paul Jannetto, Ph.D., explains how Mayo Clinic Laboratories' nicotine testing benefits patients in smoking cessation programs and other settings.
Recognizing the powerful role genes can play in diagnosing illness and guiding treatment, the Division of Laboratory Genetics and Genomics at Mayo Clinic spearheaded a testing expansion, implementing and upgrading more than 60 advanced sequencing and biochemical assays in 2023 and planning for even more this year.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, is joined by Paul Jannetto, Ph.D., director of the Clinical and Forensic Toxicology Lab, Clinical Mass Spectrometry Lab, and Metals Lab at Mayo Clinic. Dr. Pritt and Dr. Jannetto discuss the current state of the opioid crisis in the United States, its impact on public health, and the important role of laboratory testing in addiction medicine and pain management patients.
In this “Hot Topic,” Paul Jannetto, Ph.D., highlights Mayo Clinic’s targeted benzodiazepine assay and discusses the advantages and limitations of various urine-screening assays as well as quantitative confirmatory testing to determine compliance to benzodiazepine therapy.